ASND Ascendis Pharma A/S Forecast, Technical & Fundamental Analysis
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients... Show more
ASND is expected to report earnings to fall 66.53% to 94 cents per share on November 11
Q3'26
Est.
$0.95
Q2'26
Beat
by $1.32
Q1'26
Beat
by $0.09
Q4'25
Missed
by $0.40
Q3'25
Missed
by $0.72
The last earnings report on August 13 showed earnings per share of $2.83, beating the estimate of $1.51. With 147.84K shares outstanding, the current market capitalization sits at 16.61B.
A.I.dvisor indicates that over the last year, ASND has been loosely correlated with ORMP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then ORMP could also see price increases.
ASND's Stochastic Oscillator entering overbought zone
The Stochastic Oscillator for ASND moved into overbought territory on August 21, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASND as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASND declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ASND entered a downward trend on August 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ASND just turned positive on August 19, 2026. Looking at past instances where ASND's MACD turned positive, the stock continued to rise in of 57 cases over the following month. The odds of a continued upward trend are .
ASND moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ASND advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .
ASND may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ASND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.891) is normal, around the industry mean (20.145). P/E Ratio (19.395) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (13.106) is also within normal values, averaging (444.692).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
